The answer so far
Thymosin beta-4 is a naturally occurring molecule made of 43 amino acids. In its 2026 review, the US FDA described the nominated TB-500 as a chemically modified seven-amino-acid fragment related to it. They share a sequence, but a study of the longer molecule does not automatically establish what a TB-500 product does.12
On this page
Why do the names get mixed up?
People looking into injury recovery may see “TB-500” and “thymosin beta-4” used as though they were interchangeable. The attraction is understandable: thymosin beta-4 is studied in processes involved in cell movement and tissue repair, and TB-500 contains a short related sequence. But a fragment, its chemical modification, the complete formulation and its route can change what reaches tissue and what happens there. Thymosin alpha-1 is a different substance; compare all three names in the thymosin guide.1
What does the longer molecule do?
The longer molecule interacts with actin, a protein involved in cell structure and movement. Cell movement is one part of tissue repair, which is why researchers have studied the molecule in wounds and other settings. Knowing that a molecule participates in a biological process does not show that giving a particular product speeds recovery from a tendon or muscle injury.2
What did FDA mean by TB-500?
In its July 2026 briefing FDA described the nominated TB-500 as a seven-amino-acid fragment with an added chemical group, containing part of the longer molecule’s actin-related region. It also noted inconsistent names and incomplete characterisation in materials it reviewed. An online label is not independent proof that a vial matches that exact substance. Read what a certificate can and cannot establish.21
What did a study of the longer molecule find?
A 2015 randomised study assigned 72 people with dry eye to an investigational thymosin beta-4 eye solution or placebo for 28 days. Neither of the two prespecified primary measures differed significantly at the primary assessment; some secondary measures favoured the solution. This was a study of the longer molecule as eye drops for a specific eye condition, not TB-500 for tendon recovery. A mixed result in one trial does not establish that every formulation has the same effect. Follow the larger thymosin beta-4 eye trials and what they mean for TB-500.3
What about TB-500 itself?
FDA’s 2026 review said it had not identified clinical studies or human exposure data for the nominated TB-500 by any route, or published animal wound studies of that specific fragment. It described a laboratory scratch assay in fibroblast cells that did not show improved closure under the tested conditions. That narrow result does not prove what every formulation might do; it also cannot be replaced with a positive result for the longer molecule.12
How does this relate to BPC-157 and GLOW?
TB-500 is sometimes sold alongside BPC-157 or included in seller-defined GLOW and KLOW blends. A study of either ingredient, or of thymosin beta-4, does not establish the effect of the combination. Follow BPC-157 versus TB-500 for recovery, or read the TB-500 profile for product and regulatory context.14
Sources, kept close.
Selected supporting sources; this is not a complete literature review.
- FDA briefing on TB-500-related bulk drug substancesU.S. Food and Drug Administration · Advisory committee briefing; United States; July 2026
- TB-500: Pharmacy Compounding Advisory Committee briefingU.S. Food and Drug Administration · Regulatory briefing, specific nominated peptide
- Thymosin beta 4 ophthalmic solution for dry eye: a randomized, placebo-controlled, Phase II clinical trialClinical Ophthalmology / PubMed · Randomised placebo-controlled trial of full-length thymosin beta-4 eye solution; United States; 2015
- KLOW and GLOW peptide blends: what is in each vialCondor Research (seller) · Seller description; not clinical evidence